Competing immune biomarkers in the selection of first-line therapy in non-small cell lung cancer

Research output: Contribution to journalComment/debate

Original languageEnglish (US)
Pages (from-to)67-69
Number of pages3
JournalEuropean Oncology and Haematology
Issue number2
StatePublished - Jan 1 2018


  • Combination therapy
  • Immuno-chemotherapy
  • Non-small cell lung cancer
  • PD-L1
  • Pembrolizumab

ASJC Scopus subject areas

  • Hematology
  • Oncology

Cite this